Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short ...

Momentum investing is essentially an exception to the idea of "buying low and selling high." Investors following this style ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… ...

Novo Nordisk's legal actions against U.S. pharmacies over compounded copies of its drug Wegovy exclude Hims & Hers, a ...

In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug ...

Kodiak Robotics has appointed former Cruise CTO Mohamed Elshenawy to its board as it moves toward a public listing in late ...

Hims & Hers continues to spend heavily on marketing to attract new customers. During the quarter, its marketing spending ...

Hims & Hers has been an incredible stock to own over the last few years, making shareholders rich. It has $2 billion in ...

SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...

Novo Nordisk’s head of U.S. marketing, Ulrich Otte, is no longer in the role and is exploring other internal opportunities at the company outside of the U.S.

Hims & Hers Health is upgraded to a speculative Buy after a 20% drop, with growth potential in GLP-1 sales outweighing key ...